An analysis of 14,000 genomes reveals regions where new mutations are more likely to develop.

The Scandinavian island’s unique combination of genetic homogeneity, genealogical tradition, and high participation in research make it a prime location for discovery and validation of drug targets.

Researchers perform whole-genome sequencing on roughly 1 percent of the Icelandic population.

A company has been ordered to stop estimating Icelanders’ genotypes and linking them to hospital records.